This site is intended for healthcare professionals

Recognising and treating autoimmune ILDs

Read time: 60 mins
Last updated: 7th Sep 2020
Published:7th Sep 2020

Free accredited learning - Receive 1 European CME credit (ECMEC®) for successful completion

Recognising and treating autoimmune ILDs

Learn more about the burden, treatment and diagnosis of autoimmune interstitial lung diseases, then answer a series of questions designed to test your knowledge and consolidate your learning.

Successful completion of this module will earn you 1 European CME credit (ECMEC®).

Accreditation date: 7 September 2020 – 7 September 2022.

Enrol

Section 5 Assessment and closing survey  5 mins
Introduction Introduction to the CME course                 5 mins
Section 1 Burden of ILD 15 mins
Section 2 Diagnosing, screening for and monitoring ILD 20 mins
Section 3 Treatment for autoimmune ILDs                15 mins
Section 4 Emerging treatments for autoimmune ILDs 10 mins

Course overview

Quick baseline questions will be asked at the start of each section to assess your background and understanding. You will not be assessed on your responses to these questions.

Evaluation questions will be asked at the end of the module. You must achieve a score of 70% or above to pass the course and be able to print your certificate.

On completion of this course, participants will understand:

  • The various types of autoimmune ILD associated with connective tissue disorders
  • The symptomatic burden and impact on health-related quality of life (HRQoL)
  • The importance of accurate and early diagnosis
  • The risk factors for progression and mortality
  • Symptomatic treatment and the importance of managing the underlying disease
  • Emerging treatment options

System Requirements

Faculty

Professor Kristin Highland. Associate Program Director for Research and Scholarly Activity and Director of the Rheumatic Lung Disease Programme and an active member of the Interstitial Lung Disease and Pulmonary Hypertension programmes at the Cleveland clinic/Respiratory Institute, Ohio, US.

Dr Anna-Maria Hoffmann-Vold. Clinical scientist in the Department of Rheumatology, Oslo University Hospital, Oslo, Norway and head of scleroderma research at Oslo University Hospital. Her recent research projects have focused on systemic sclerosis (SSc) with a main focus on interstitial lung disease (ILD), pulmonary arterial hypertension (PAH) and gut microbiota.

Welcome:

This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.